What is he best known for?
The fields of study he is best known for:
Erwin G. Van Meir mainly focuses on Cancer research, Glioma, Angiogenesis, Pathology and Tumor suppressor gene.
The concepts of his Cancer research study are interwoven with issues in Cancer, Tumor heterogeneity, Reprogramming and Exome.
His Glioma research incorporates elements of Camptothecin, Vincristine, Hypoxia and Doxorubicin.
He combines subjects such as Chemokine, Tumor progression, CXC chemokine receptors and Interleukin 8 with his study of Angiogenesis.
His Pathology study combines topics from a wide range of disciplines, such as Young adult, Cell culture, Astrocytoma and Tissue factor.
As a member of one scientific family, Erwin G. Van Meir mostly works in the field of Genomics, focusing on Epigenetics and, on occasion, DNA methylation.
His most cited work include:
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (5484 citations)
- The Somatic Genomic Landscape of Glioblastoma (2550 citations)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (1510 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Cancer research, Glioma, Angiogenesis, Pathology and Cell biology.
Erwin G. Van Meir has included themes like Tumor suppressor gene, Cancer, Transcription factor and Hypoxia in his Cancer research study.
His research in Glioma tackles topics such as Brain tumor which are related to areas like Cerebrospinal fluid and Bioinformatics.
His Angiogenesis research includes themes of Endocrinology and Vascular endothelial growth factor.
His research in Cell biology intersects with topics in Receptor, Cell culture, Genetics and Angiogenesis inhibitor.
While the research belongs to areas of Medulloblastoma, Erwin G. Van Meir spends his time largely on the problem of Epigenetics, intersecting his research to questions surrounding DNA methylation.
He most often published in these fields:
- Cancer research (55.71%)
- Glioma (27.85%)
- Angiogenesis (16.89%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (55.71%)
- Medulloblastoma (10.05%)
- Epigenetics (5.02%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Medulloblastoma, Epigenetics, Wnt signaling pathway and Gene.
Erwin G. Van Meir works on Cancer research which deals in particular with Glioma.
He works mostly in the field of Glioma, limiting it down to topics relating to Phenotype and, in certain cases, Somatic evolution in cancer and Disease, as a part of the same area of interest.
His Medulloblastoma research integrates issues from Internal medicine and Oncology.
His research integrates issues of Cerebellum, Granular cell, DNA methylation, P53 Tumor Suppressor and Mesenchymal stem cell in his study of Epigenetics.
His work in Gene covers topics such as Signal transduction which are related to areas like Intracellular, HMGA2 and Mutation rate.
Between 2017 and 2021, his most popular works were:
- Pan-cancer analysis of whole genomes (538 citations)
- Genomic and Functional Approaches to Understanding Cancer Aneuploidy (296 citations)
- Erratum: Comprehensive Characterization of Cancer Driver Genes and Mutations (ARTICLE (2018) 173(2) (371–385), (S009286741830237X), (10.1016/j.cell.2018.02.060)) (147 citations)
In his most recent research, the most cited papers focused on:
His primary scientific interests are in Cancer research, Gene, microRNA, DNA methylation and Germline mutation.
His primary area of study in Cancer research is in the field of Diffuse Glioma.
His Gene study typically links adjacent topics like Medulloblastoma.
The various areas that he examines in his Germline mutation study include Point mutation, Genome, Whole genome sequencing and Germline.
His Genome study is concerned with the larger field of Genetics.
Erwin G. Van Meir usually deals with Genomics and limits it to topics linked to Molecular evolution and Glioma, Phenotype, Internal medicine and Oncology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
